1.	Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Prevention Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-02541, MDA-ID-00193, P50CA097007, CDR0000306522, NCI-6053, 6053, NCT00064103
2.	Phase II Randomized Study of Two Treatment Regimens of Recombinant Adenoviral p53 Gene (Ad5CMV-p53 gene) Administered by Intratumoral Injections in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 07/1999) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: RP-T-201, SCCC-97050, NCI-V98-1393
3.	Phase II Study of Ad5CMV-p53 in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Summary Last Modified 04/2000). Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AVENTIS-T-202, MCC-11653, RP-T-202, NCI-V98-1394, NCT00003257
4.	Phase II Study of Docetaxel, Doxorubicin, and Ad5CMV-p53 Gene Therapy (INGN 201) in Patients With Locally Advanced Breast Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: INTROGEN-201-010, MDA-ID-00008, NCT00044993
5.	Gene Therapy in Treating Patients With Advanced Bladder Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-02261, MDA-DM-96172, R21CA076233, CDR0000065968, NCI-T96-0073, T96-0073, NCT00003167
6.	Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: Over 18 Sponsor: NCI Protocol IDs: NCI-2012-02273, FCCC-97009, NCI-T97-0042, CDR0000066480, T97-0042, NCT00004038
7.	Gene Therapy in Treating Patients With Ovarian Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-02277, MDA-ID-97228, NCI-T97-0111, CDR0000066657, T97-0111, NCT00003588
8.	Gene Therapy in Treating Patients With Non-Small Cell Lung Cancer That Cannot Be Surgically Removed Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000066741, E-6597, NCT00003649
9.	Gene Therapy in Treating Patients With Recurrent Malignant Gliomas Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000066871, NABTC-9703, NCT00004041
10.	Phase I Pilot Study of Adenovirus p53 Gene Therapy and Radiotherapy in Patients With Non-Small Cell Lung Cancer Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-8597, E8597, NCT00004225
11.	Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000066481, UTSMC-089733300, NCI-T97-0096, T97-0096, NCT00003450